Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VEGFR-2 inhibitor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3 result(s) found for: VEGFR-2 inhibitor. Displaying page 1 of 1.
    EudraCT Number: 2005-000317-35 Sponsor Protocol Number: 1199.10 Start Date*: 2005-07-06
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-s...
    Medical condition: Relapsed non-small-cell lunger cancer patients stage IIIB and stage IV after previous treatment with platinum- or non-platinum based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    7.1 10061873 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000051-15 Sponsor Protocol Number: A4061008 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical Trials
    Medical condition: Patients who have been treated in previous AG-013736 oncology studies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000971-33 Sponsor Protocol Number: A4061010 Start Date*: 2004-09-24
    Sponsor Name:PFIZER
    Full Title: Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of AG-013736 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Preceded by a Phase 1 Evaluat...
    Medical condition: METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 07:09:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA